Primary Tumor Radiotherapy During EGFR-TKI Disease Control Improves Survival of Treatment Naïve Advanced EGFR-Mutant Lung Adenocarcinoma Patients
Journal
OncoTargets and therapy
Journal Volume
14
Date Issued
2021
Author(s)
Hsu, Kuo-Hsuan
Huang, Jing-Wen
Tseng, Jeng-Sen
Chen, Kuan-Wen
Weng, Yih-Chyang
Yang, Tsung-Ying
Huang, Yen-Hsiang
Chen, Jeremy J W
Chen, Kun-Chieh
Chang, Gee-Chen
Abstract
Whether radiotherapy only for primary lung tumor (RTPLT) after epidermal growth factor receptor (EGFR)-tyrosine kinase inhibitor (TKI) therapy improves survival of treatment naïve advanced EGFR-mutant lung adenocarcinoma (LAD) patients with/without polymetastasis.
Subjects
EGFR-TKI; RTPLT; lung adenocarcinoma; oligometastasis; polymetastasis; radiotherapy to primary lung tumor
SDGs
Other Subjects
afatinib; epidermal growth factor receptor kinase inhibitor; erlotinib; gefitinib; osimertinib; adult; aged; Article; bone metastasis; brain metastasis; cancer control; cancer radiotherapy; cancer staging; controlled study; female; human; liver metastasis; lung adenocarcinoma; major clinical study; male; multivariate analysis; observational study; overall survival; progression free survival; radiation pneumonia; retrospective study
Type
journal article